The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
As of close of business last night, Allogene Therapeutics Inc’s stock clocked out at $1.37, up 2.24% from its previous closing price of $1.34. In other words, the price has increased by $2.24 from its previous closing price. On the day, 1.76 million shares were traded.
Ratios:
To gain a deeper understanding of ALLO’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 9.71 and its Current Ratio is at 9.71. In the meantime, Its Debt-to-Equity ratio is 0.23 whereas as Long-Term Debt/Eq ratio is at 0.21.
On March 14, 2025, Citizens JMP Upgraded its rating to Mkt Outperform which previously was Mkt Perform but kept the price unchanged to $5.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jun 10 ’25 when MESSEMER DEBORAH M. sold 36,885 shares for $1.42 per share. The transaction valued at 52,377 led to the insider holds 107,431 shares of the business.
MESSEMER DEBORAH M. bought 36,885 shares of ALLO for $52,391 on Jun 10 ’25. On Apr 21 ’25, another insider, Yoshiyama Annie, who serves as the SVP, Finance of the company, sold 9,601 shares for $1.41 each. As a result, the insider received 13,537 and left with 130,663 shares of the company.
Stock Price History:
Over the past 52 weeks, ALLO has reached a high of $3.78, while it has fallen to a 52-week low of $0.86. The 50-Day Moving Average of the stock is 2.01%, while the 200-Day Moving Average is calculated to be -32.28%.
Shares Statistics:
A total of 218.60M shares are outstanding, with a floating share count of 149.51M. Insiders hold about 31.65% of the company’s shares, while institutions hold 66.02% stake in the company.
